Alessio Ciminna

Dr. Alessio Ciminna


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MGMartina Greco
Martina Greco
CCCalogero Cipolla
Calogero Cipolla
CMChiara Mesi
Chiara Mesi
ACAlessio Ciminna
Alessio Ciminna
DSDaniela Sambataro
Daniela Sambataro
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Surgical resection of liver and lung metastases in breast cancer is increasingly considered a viable option for select patients with oligometastatic disease. Historically regarded as palliative, surgery is now supported by retrospective data suggesting potential survival benefits, particularly in patients with hormone receptor-positive or HER2-positive tumors, long disease-free intervals, and limited metastatic burden. This narrative review summarizes recent evidence on the surgical management of breast cancer metastases to the liver and lung, with a focus on patient selection, perioperative outcomes, and long-term survival. Liver metastasectomy has shown 5-year overall survival rates of up to 60% in well-selected patients, while pulmonary metastasectomy is associated with comparable outcomes when resection is complete and nodal involvement is absent. Minimally invasive techniques and non-surgical approaches, such as microwave ablation and stereotactic radiotherapy, expand treatment options for patients unfit for surgery. The review also explores emerging tools influencing surgical decision-making, including circulating tumor DNA for minimal residual disease detection, transcriptomic profiling to predict organotropism, and artificial intelligence (AI)-driven platforms that assist with surgical planning and multidisciplinary case evaluation. While prospective validation remains limited, these technologies may help redefine surgical candidacy through biologically informed algorithms. Ultimately, the integration of surgery within a multimodal, personalized treatment strategy—guided by systemic control, tumor biology, and evolving digital tools—represents an evolving and biologically informed direction for rigorously selected patients with visceral breast cancer metastases.

30 December 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
DSDaniela Sambataro
Daniela Sambataro
GSGiuseppa Scandurra
Giuseppa Scandurra
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
MGMartina Greco
Martina Greco
ACAlessio Ciminna
Alessio Ciminna
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Magnesium (Mg2+) has garnered the attention of oncologists due to its wide range of biological functions and frequent use as a complementary or integrative agent. In this study, a concise narrative review of the complex relationships between Mg2+ and immunotherapy for human malignancies is presented, in addition to a possible future therapeutic scenario. Pertinent full-text articles were thoroughly examined, and the most relevant ones were selected for inclusion in this review. A significant body of preclinical studies highlights the role of Mg2+ in regulating immune function, particularly in cytotoxic effector cells, underscoring the importance of maintaining adequate Mg2+ homeostasis mainly when immune-modulating agents are used in clinical practice. Whether serum Mg2+ levels influence the clinical outcomes of cancer patients treated with immune checkpoint blocker treatment remains to be fully elucidated. However, over the last decade, an increasing amount of data suggests that maintaining normal or slightly elevated serum levels of Mg2+ may enhance the response to immune therapy and even improve survival outcomes. New potential modulators of the tumor microenvironment and response to immunotherapy, such as injectable gels and metal-based biomaterials, are discussed.

20 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMartina Greco
Martina Greco
CCCalogero Cipolla
Calogero Cipolla
CMChiara Mesi
Chiara Mesi
ACAlessio Ciminna
Alessio Ciminna
DSDaniela Sambataro
Daniela Sambataro
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Surgical resection of liver and lung metastases in breast cancer is increasingly considered a viable option for select patients with oligometastatic disease. Historically regarded as palliative, surgery is now supported by retrospective data suggesting potential survival benefits, particularly in patients with hormone receptor-positive or HER2-positive tumors, long disease-free intervals, and limited metastatic burden. This narrative review summarizes recent evidence on the surgical management of breast cancer metastases to the liver and lung, with a focus on patient selection, perioperative outcomes, and long-term survival. Liver metastasectomy has shown 5-year overall survival rates of up to 60% in well-selected patients, while pulmonary metastasectomy offers comparable outcomes when resection is complete and nodal involvement is absent. Minimally invasive techniques and non-surgical approaches, such as microwave ablation and stereotactic radiotherapy, expand treatment options for patients unfit for surgery. The review also explores emerging tools influencing surgical decision-making, including circulating tumor DNA for minimal residual disease detection, transcriptomic profiling to predict organotropism, and artificial intelligence (AI)-driven platforms that assist with surgical planning and multidisciplinary case evaluation. While prospective validation remains limited, these technologies may help redefine surgical candidacy through biologically informed algorithms. Ultimately, the integration of surgery within a multimodal, personalized treatment strategy – guided by systemic control, tumor biology, and evolving digital tools – represents a promising direction for selected patients with visceral breast cancer metastases.

17 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Vittorio GebbiaVittorio Gebbia
Vittorio Gebbia
RVRoberto Valenza
Roberto Valenza
IFIvan Fazio
Ivan Fazio
PDPietro angelo Delia
Pietro angelo Delia
MGMartina Greco
Martina Greco
MVMaria Rosaria Valerio
Maria Rosaria Valerio
Background/Objectives: Cancer-related fatigue is one of the most distressing symptoms complained by neoplastic patients. L-arginine has a positive effect on physical performance in normal individuals, on fatigue in diseases other than cancer and on immune response in cancer patients. Methods: Forty-four cancer patients undergoing medical treatment were treated with oral l-arginine 1.66 g and 500 mg of vitamin C b.i.d. Cancer-related fatigue and health-related quality of life were recorded before treatment and after 15 and 30 days employing a visual analog scale and the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) respectively. Results: Daily oral supplementation with l-arginine and vitamin C ameliorated cancer-related fatigue in a statistically significant manner. Health-related quality of life remained mostly unchanged despite patients had advanced cancer and were administered medical treatments including chemotherapy, immunotherapy and biologics. No effect on appetite preservation was observed but in a small percentage of patients Conclusions: Our exploratory study suggests a positive effect of oral supplementation with l-arginine plus vitamin C on cancer related fatigue without significant worsening of quality of life. Due to the heterogeneity of patients sample further studies are needed including more clinically homogenous groups of patients.